Mechanistic studies indicate that the combination of PARP inhibitors and radiotherapy promotes tumor cell senescence by inducing cumulative DNA damage, triggering increased p21 expression and elevated β-galactosidase activity. This evidence concerns the gene PARP1 and neoplasm.